Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence.

Petzold A, Braithwaite T, van Oosten BW, Balk L, Martinez-Lapiscina EH, Wheeler R, Wiegerinck N, Waters C, Plant GT.

J Neurol Neurosurg Psychiatry. 2019 Nov 18. pii: jnnp-2019-321653. doi: 10.1136/jnnp-2019-321653. [Epub ahead of print] No abstract available.

2.

Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors.

Sepúlveda M, Montejo C, Llufriu S, Sola-Valls N, Reyes D, Martinez-Lapiscina EH, Zubizarreta I, Pulido-Valdeolivas I, Martinez-Hernandez E, Ariño H, Baños N, Saiz A, Blanco Y.

Mult Scler Relat Disord. 2019 Oct 30;38:101483. doi: 10.1016/j.msard.2019.101483. [Epub ahead of print]

PMID:
31734621
3.

Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis.

Andorrà M, Alba-Arbalat S, Camos-Carreras A, Gabilondo I, Fraga-Pumar E, Torres-Torres R, Pulido-Valdeolivas I, Tercero-Uribe AI, Guerrero-Zamora AM, Ortiz-Perez S, Zubizarreta I, Sola-Valls N, Llufriu S, Sepulveda M, Martinez-Hernandez E, Armangue T, Blanco Y, Villoslada P, Sanchez-Dalmau B, Saiz A, Martinez-Lapiscina EH.

JAMA Neurol. 2019 Sep 30. doi: 10.1001/jamaneurol.2019.3283. [Epub ahead of print]

PMID:
31566686
4.

Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study.

Balk LJ, Coric D, Knier B, Zimmermann HG, Behbehani R, Alroughani R, Martinez-Lapiscina EH, Brandt AU, Sánchez-Dalmau B, Vidal-Jordana A, Albrecht P, Koska V, Havla J, Pisa M, Nolan RC, Leocani L, Paul F, Aktas O, Montalban X, Balcer LJ, Villoslada P, Outteryck O, Korn T, Petzold A; IMSVISUAL consortium.

Mult Scler J Exp Transl Clin. 2019 Sep 5;5(3):2055217319871582. doi: 10.1177/2055217319871582. eCollection 2019 Jul-Sep.

5.

Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus.

Sepulveda M, Delgado-García G, Blanco Y, Sola-Valls N, Martinez-Lapiscina EH, Armangué T, Montejo C, Pulido-Valdeolivas I, Martinez-Hernandez E, Ariño H, Escudero D, Ruiz-García R, Llufriu S, Dalmau J, Graus F, Saiz A.

Neurol Neuroimmunol Neuroinflamm. 2019 Aug 30;6(6). pii: e607. doi: 10.1212/NXI.0000000000000607. Print 2019 Nov.

6.

Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial.

Zubizarreta I, Flórez-Grau G, Vila G, Cabezón R, España C, Andorra M, Saiz A, Llufriu S, Sepulveda M, Sola-Valls N, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Casanova B, Martinez Gines M, Tellez N, Oreja-Guevara C, Español M, Trias E, Cid J, Juan M, Lozano M, Blanco Y, Steinman L, Benitez-Ribas D, Villoslada P.

Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8463-8470. doi: 10.1073/pnas.1820039116. Epub 2019 Apr 8.

7.

Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study.

Nolan-Kenney RC, Liu M, Akhand O, Calabresi PA, Paul F, Petzold A, Balk L, Brandt AU, Martínez-Lapiscina EH, Saidha S, Villoslada P, Al-Hassan AA, Behbehani R, Frohman EM, Frohman T, Havla J, Hemmer B, Jiang H, Knier B, Korn T, Leocani L, Papadopoulou A, Pisa M, Zimmermann H, Galetta SL, Balcer LJ; International Multiple Sclerosis Visual System Consortium.

Ann Neurol. 2019 May;85(5):618-629. doi: 10.1002/ana.25462. Epub 2019 Apr 10.

PMID:
30851125
8.

Reporting of R2 Statistics for Mixed-Effects Regression Models-Reply.

Andorra M, Martinez-Lapiscina EH.

JAMA Neurol. 2019 Apr 1;76(4):507-508. doi: 10.1001/jamaneurol.2018.4723. No abstract available.

PMID:
30715081
9.

Remyelination: a good neuroprotective strategy for preventing axonal degeneration?

Villoslada P, Martinez-Lapiscina EH.

Brain. 2019 Feb 1;142(2):233-236. doi: 10.1093/brain/awy349. No abstract available.

PMID:
30698759
10.

Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease.

Pedreño M, Sepúlveda M, Armangué T, Sabater L, Martínez-Hernandez E, Arrambide G, Blanco Y, Llufriu S, Martínez-Lapiscina EH, Mulero P, Sola-Valls N, Ruiz-García R, Tintoré M, Dalmau J, Graus F, Saiz A.

Mult Scler Relat Disord. 2019 Feb;28:230-234. doi: 10.1016/j.msard.2019.01.007. Epub 2019 Jan 3.

PMID:
30623863
11.

Spanish validation of the telephone assessed Expanded Disability Status Scale and Patient Determined Disease Steps in people with multiple sclerosis.

Solà-Valls N, Vicente-Pascual M, Blanco Y, Solana E, Llufriu S, Martínez-Heras E, Martínez-Lapiscina EH, Sepúlveda M, Pulido-Valdeolivas I, Zubizarreta I, Saiz A.

Mult Scler Relat Disord. 2019 Jan;27:333-339. doi: 10.1016/j.msard.2018.11.018. Epub 2018 Nov 19.

PMID:
30472411
12.

The International Multiple Sclerosis Visual System Consortium: Advancing Visual System Research in Multiple Sclerosis.

Balcer LJ, Balk LJ, Brandt AU, Calabresi PA, Martinez-Lapiscina EH, Nolan RC, Paul F, Petzold A, Saidha S.

J Neuroophthalmol. 2018 Dec;38(4):494-501. doi: 10.1097/WNO.0000000000000732.

PMID:
30418332
13.

Magnetic resonance markers of tissue damage related to connectivity disruption in multiple sclerosis.

Solana E, Martinez-Heras E, Martinez-Lapiscina EH, Sepulveda M, Sola-Valls N, Bargalló N, Berenguer J, Blanco Y, Andorra M, Pulido-Valdeolivas I, Zubizarreta I, Saiz A, Llufriu S.

Neuroimage Clin. 2018 Jul 12;20:161-168. doi: 10.1016/j.nicl.2018.07.012. eCollection 2018.

14.

Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine.

Sola-Valls N, Blanco Y, Sepúlveda M, Llufriu S, Martínez-Lapiscina EH, Zubizarreta I, Pulido-Valdeolivas I, Montejo C, Villoslada P, Saiz A.

Ther Adv Neurol Disord. 2018 Jun 10;11:1756286418780007. doi: 10.1177/1756286418780007. eCollection 2018.

15.

Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis.

Andorra M, Nakamura K, Lampert EJ, Pulido-Valdeolivas I, Zubizarreta I, Llufriu S, Martinez-Heras E, Sola-Valls N, Sepulveda M, Tercero-Uribe A, Blanco Y, Saiz A, Villoslada P, Martinez-Lapiscina EH.

JAMA Neurol. 2018 Oct 1;75(10):1246-1255. doi: 10.1001/jamaneurol.2018.1596.

16.

Predictors of vision impairment in Multiple Sclerosis.

Sanchez-Dalmau B, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Zubizarreta I, Llufriu S, Blanco Y, Sola-Valls N, Sepulveda M, Guerrero A, Alba S, Andorra M, Camos A, Sanchez-Vela L, Alfonso V, Saiz A, Villoslada P.

PLoS One. 2018 Apr 17;13(4):e0195856. doi: 10.1371/journal.pone.0195856. eCollection 2018.

17.

Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon.

Sobhanian MJ, Agarwal R, Meltzer E, Kildebeck E, Frohman BS, Frohman AN, Galetta SL, Saidha S, White O, Villoslada P, Paul F, Petzold A, Rennaker RL, Martinez-Lapiscina EH, Balcer LJ, Kardon R, Frohman EM, Frohman TC.

J Neurol Sci. 2018 Apr 15;387:60-69. doi: 10.1016/j.jns.2018.01.029. Epub 2018 Feb 3.

PMID:
29571874
18.

The popularity of neurology in Spain: An analysis of specialty selection.

Curbelo J, Romeo JM, Galván-Román JM, Vega-Villar J, Martinez-Lapiscina EH, Jiménez-Fonseca P, Villacampa T, Sánchez-Lasheras F, Fernández-Somoano A, Baladrón J.

Neurologia. 2017 Dec 23. pii: S0213-4853(17)30361-4. doi: 10.1016/j.nrl.2017.10.011. [Epub ahead of print] English, Spanish.

19.

Time is vision: The importance of the early discovery and diagnosis of optic neuritis.

Villoslada P, Martinez-Lapiscina EH.

Mult Scler. 2017 Dec;23(14):1806-1807. doi: 10.1177/1352458517739140. No abstract available.

PMID:
29154727
20.

Dynamics and heterogeneity of brain damage in multiple sclerosis.

Kotelnikova E, Kiani NA, Abad E, Martinez-Lapiscina EH, Andorra M, Zubizarreta I, Pulido-Valdeolivas I, Pertsovskaya I, Alexopoulos LG, Olsson T, Martin R, Paul F, Tegnér J, Garcia-Ojalvo J, Villoslada P.

PLoS Comput Biol. 2017 Oct 26;13(10):e1005757. doi: 10.1371/journal.pcbi.1005757. eCollection 2017 Oct.

21.

Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.

Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, Martinez-Lapiscina EH, Green AJ, Kardon R, Outteryck O, Paul F, Schippling S, Vermersch P, Villoslada P, Balk LJ; ERN-EYE IMSVISUAL.

Lancet Neurol. 2017 Oct;16(10):797-812. doi: 10.1016/S1474-4422(17)30278-8. Epub 2017 Sep 12. Review.

PMID:
28920886
22.

Early retinal atrophy predicts long-term visual impairment after acute optic neuritis.

Sanchez-Dalmau B, Martinez-Lapiscina EH, Torres-Torres R, Ortiz-Perez S, Zubizarreta I, Pulido-Valdeolivas IV, Alba-Arbalat S, Guerrero-Zamora A, Calbet D, Villoslada P.

Mult Scler. 2018 Aug;24(9):1196-1204. doi: 10.1177/1352458517718628. Epub 2017 Jul 3.

PMID:
28669275
23.

Monitoring the Course of MS With Optical Coherence Tomography.

Brandt AU, Martinez-Lapiscina EH, Nolan R, Saidha S.

Curr Treat Options Neurol. 2017 Apr;19(4):15. doi: 10.1007/s11940-017-0452-7. Review.

PMID:
28374232
24.

Structural networks involved in attention and executive functions in multiple sclerosis.

Llufriu S, Martinez-Heras E, Solana E, Sola-Valls N, Sepulveda M, Blanco Y, Martinez-Lapiscina EH, Andorra M, Villoslada P, Prats-Galino A, Saiz A.

Neuroimage Clin. 2016 Dec 5;13:288-296. doi: 10.1016/j.nicl.2016.11.026. eCollection 2017.

25.

Impairment of decision-making in multiple sclerosis: A neuroeconomic approach.

Sepúlveda M, Fernández-Diez B, Martínez-Lapiscina EH, Llufriu S, Sola-Valls N, Zubizarreta I, Blanco Y, Saiz A, Levy D, Glimcher P, Villoslada P.

Mult Scler. 2017 Nov;23(13):1762-1771. doi: 10.1177/1352458516682103. Epub 2016 Dec 7.

26.

Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders.

Martinez-Lapiscina EH, Sepulveda M, Torres-Torres R, Alba-Arbalat S, Llufriu S, Blanco Y, Guerrero-Zamora AM, Sola-Valls N, Ortiz-Perez S, Villoslada P, Sanchez-Dalmau B, Saiz A.

Ther Adv Neurol Disord. 2016 Sep;9(5):436-40. doi: 10.1177/1756285616655264. Epub 2016 Aug 15. No abstract available.

27.

Phenytoin for neuroprotection.

Martinez-Lapiscina EH, Andorra M, Sanchez-Dalmau B, Villoslada P.

Lancet Neurol. 2016 Aug;15(9):901-902. doi: 10.1016/S1474-4422(16)30093-X. No abstract available.

PMID:
27478946
28.

The APOSTEL recommendations for reporting quantitative optical coherence tomography studies.

Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, Saidha S, Martinez-Lapiscina EH, Lagreze WA, Schuman JS, Villoslada P, Calabresi P, Balcer L, Petzold A, Green AJ, Paul F, Brandt AU, Albrecht P; IMSVISUAL consortium.

Neurology. 2016 Jun 14;86(24):2303-9. doi: 10.1212/WNL.0000000000002774. Epub 2016 May 25.

29.

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.

Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium.

Lancet Neurol. 2016 May;15(6):574-84. doi: 10.1016/S1474-4422(16)00068-5. Epub 2016 Mar 18.

PMID:
27011339
30.

Visual field impairment captures disease burden in multiple sclerosis.

Ortiz-Perez S, Andorra M, Sanchez-Dalmau B, Torres-Torres R, Calbet D, Lampert EJ, Alba-Arbalat S, Guerrero-Zamora AM, Zubizarreta I, Sola-Valls N, Llufriu S, Sepúlveda M, Saiz A, Villoslada P, Martinez-Lapiscina EH.

J Neurol. 2016 Apr;263(4):695-702. doi: 10.1007/s00415-016-8034-2. Epub 2016 Feb 9.

PMID:
26860093
31.

Improved Framework for Tractography Reconstruction of the Optic Radiation.

Martínez-Heras E, Varriano F, Prčkovska V, Laredo C, Andorrà M, Martínez-Lapiscina EH, Calvo A, Lampert E, Villoslada P, Saiz A, Prats-Galino A, Llufriu S.

PLoS One. 2015 Sep 16;10(9):e0137064. doi: 10.1371/journal.pone.0137064. eCollection 2015.

32.

Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study.

Sepúlveda M, Ros C, Martínez-Lapiscina EH, Solà-Valls N, Hervàs M, Llufriu S, La Puma D, Casals E, Blanco Y, Villoslada P, Graus F, Castelo-Branco C, Saiz A.

Mult Scler. 2016 Apr;22(4):564-8. doi: 10.1177/1352458515602339. Epub 2015 Sep 11.

PMID:
26362892
33.

The analysis of semantic networks in multiple sclerosis identifies preferential damage of long-range connectivity.

Abad E, Sepulcre J, Martinez-Lapiscina EH, Zubizarreta I, Garcia-Ojalvo J, Villoslada P.

Mult Scler Relat Disord. 2015 Sep;4(5):387-394. doi: 10.1016/j.msard.2015.07.002. Epub 2015 Jul 8.

PMID:
26346784
34.

Color vision impairment in multiple sclerosis points to retinal ganglion cell damage.

Lampert EJ, Andorra M, Torres-Torres R, Ortiz-Pérez S, Llufriu S, Sepúlveda M, Sola N, Saiz A, Sánchez-Dalmau B, Villoslada P, Martínez-Lapiscina EH.

J Neurol. 2015 Nov;262(11):2491-7. doi: 10.1007/s00415-015-7876-3. Epub 2015 Aug 11.

PMID:
26259563
35.

Mediterranean Diet and Age-Related Cognitive Decline: A Randomized Clinical Trial.

Valls-Pedret C, Sala-Vila A, Serra-Mir M, Corella D, de la Torre R, Martínez-González MÁ, Martínez-Lapiscina EH, Fitó M, Pérez-Heras A, Salas-Salvadó J, Estruch R, Ros E.

JAMA Intern Med. 2015 Jul;175(7):1094-1103. doi: 10.1001/jamainternmed.2015.1668. Erratum in: JAMA Intern Med. 2018 Dec 1;178(12):1731-1732.

36.

Walking function in clinical monitoring of multiple sclerosis by telemedicine.

Sola-Valls N, Blanco Y, Sepúlveda M, Llufriu S, Martínez-Lapiscina EH, La Puma D, Graus F, Villoslada P, Saiz A.

J Neurol. 2015 Jul;262(7):1706-13. doi: 10.1007/s00415-015-7764-x. Epub 2015 May 10.

PMID:
25957639
37.

Knowledge retrieval from PubMed abstracts and electronic medical records with the Multiple Sclerosis Ontology.

Malhotra A, Gündel M, Rajput AM, Mevissen HT, Saiz A, Pastor X, Lozano-Rubi R, Martinez-Lapiscina EH, Zubizarreta I, Mueller B, Kotelnikova E, Toldo L, Hofmann-Apitius M, Villoslada P.

PLoS One. 2015 Feb 9;10(2):e0116718. doi: 10.1371/journal.pone.0116718. eCollection 2015. Erratum in: PLoS One. 2015;10(3):e0122614. Martinez-Lapsicina, Elena H [corrected to Martinez-Lapiscina, Elena H]. PLoS One. 2015 Mar 13;10(3):e0122614.

38.

Dynamics of retinal injury after acute optic neuritis.

Gabilondo I, Martínez-Lapiscina EH, Fraga-Pumar E, Ortiz-Perez S, Torres-Torres R, Andorra M, Llufriu S, Zubizarreta I, Saiz A, Sanchez-Dalmau B, Villoslada P.

Ann Neurol. 2015 Mar;77(3):517-28. doi: 10.1002/ana.24351. Epub 2015 Feb 14.

PMID:
25559267
39.

The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS.

Martínez-Lapiscina EH, Fraga-Pumar E, Gabilondo I, Martínez-Heras E, Torres-Torres R, Ortiz-Pérez S, Llufriu S, Tercero A, Andorra M, Roca MF, Lampert E, Zubizarreta I, Saiz A, Sanchez-Dalmau B, Villoslada P.

BMC Res Notes. 2014 Dec 15;7:910. doi: 10.1186/1756-0500-7-910.

40.

The visual pathway as a model to understand brain damage in multiple sclerosis.

Martínez-Lapiscina EH, Sanchez-Dalmau B, Fraga-Pumar E, Ortiz-Perez S, Tercero-Uribe AI, Torres-Torres R, Villoslada P.

Mult Scler. 2014 Nov;20(13):1678-85. doi: 10.1177/1352458514542862. Epub 2014 Jul 10. Review.

PMID:
25013155
41.

Genotype patterns at CLU, CR1, PICALM and APOE, cognition and Mediterranean diet: the PREDIMED-NAVARRA trial.

Martínez-Lapiscina EH, Galbete C, Corella D, Toledo E, Buil-Cosiales P, Salas-Salvado J, Ros E, Martinez-Gonzalez MA.

Genes Nutr. 2014 May;9(3):393. doi: 10.1007/s12263-014-0393-7. Epub 2014 Mar 19.

42.

Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008-2012.

Martínez-Lapiscina EH, Fraga-Pumar E, Pastor X, Gómez M, Conesa A, Lozano-Rubí R, Sánchez-Dalmau B, Alonso A, Villoslada P.

J Neurol. 2014 Apr;261(4):759-67. doi: 10.1007/s00415-014-7266-2. Epub 2014 Feb 16.

PMID:
24532201
43.

Colour vision impairment is associated with disease severity in multiple sclerosis.

Martínez-Lapiscina EH, Ortiz-Pérez S, Fraga-Pumar E, Martínez-Heras E, Gabilondo I, Llufriu S, Bullich S, Figueras M, Saiz A, Sánchez-Dalmau B, Villoslada P.

Mult Scler. 2014 Aug;20(9):1207-16. doi: 10.1177/1352458513517591. Epub 2014 Jan 7.

PMID:
24399824
44.

Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.

Gabilondo I, Martínez-Lapiscina EH, Martínez-Heras E, Fraga-Pumar E, Llufriu S, Ortiz S, Bullich S, Sepulveda M, Falcon C, Berenguer J, Saiz A, Sanchez-Dalmau B, Villoslada P.

Ann Neurol. 2014 Jan;75(1):98-107. doi: 10.1002/ana.24030. Epub 2014 Jan 2.

PMID:
24114885
45.

Dynamic molecular monitoring of retina inflammation by in vivo Raman spectroscopy coupled with multivariate analysis.

Marro M, Taubes A, Abernathy A, Balint S, Moreno B, Sanchez-Dalmau B, Martínez-Lapiscina EH, Amat-Roldan I, Petrov D, Villoslada P.

J Biophotonics. 2014 Sep;7(9):724-34. doi: 10.1002/jbio.201300101. Epub 2013 Sep 6.

PMID:
24019106
46.

Retinal periphlebitis is associated with multiple sclerosis severity.

Ortiz-Pérez S, Martínez-Lapiscina EH, Gabilondo I, Fraga-Pumar E, Martínez-Heras E, Saiz A, Sanchez-Dalmau B, Villoslada P.

Neurology. 2013 Sep 3;81(10):877-81. doi: 10.1212/WNL.0b013e3182a3525e. Epub 2013 Jul 31.

47.

Virgin olive oil supplementation and long-term cognition: the PREDIMED-NAVARRA randomized, trial.

Martínez-Lapiscina EH, Clavero P, Toledo E, San Julián B, Sanchez-Tainta A, Corella D, Lamuela-Raventós RM, Martínez JA, Martínez-Gonzalez MÁ.

J Nutr Health Aging. 2013;17(6):544-52. doi: 10.1007/s12603-013-0027-6.

PMID:
23732551
48.

Retrograde retinal damage after acute optic tract lesion in MS.

Gabilondo I, Sepúlveda M, Ortiz-Perez S, Fraga-Pumar E, Martínez-Lapiscina EH, Llufriu S, Solá N, Saiz A, Sanchez-Dalmau B, Villoslada P.

J Neurol Neurosurg Psychiatry. 2013 Jul;84(7):824-6. doi: 10.1136/jnnp-2012-304854. Epub 2013 May 28. No abstract available.

PMID:
23715916
49.

Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial.

Martínez-Lapiscina EH, Clavero P, Toledo E, Estruch R, Salas-Salvadó J, San Julián B, Sanchez-Tainta A, Ros E, Valls-Pedret C, Martinez-Gonzalez MÁ.

J Neurol Neurosurg Psychiatry. 2013 Dec;84(12):1318-25. doi: 10.1136/jnnp-2012-304792. Epub 2013 May 13.

PMID:
23670794
50.

Cortico-juxtacortical involvement increases risk of epileptic seizures in multiple sclerosis.

Martínez-Lapiscina EH, Ayuso T, Lacruz F, Gurtubay IG, Soriano G, Otano M, Bujanda M, Bacaicoa MC.

Acta Neurol Scand. 2013 Jul;128(1):24-31. doi: 10.1111/ane.12064. Epub 2013 Jan 7.

PMID:
23289848

Supplemental Content

Loading ...
Support Center